MX2023004352A - Esteroides neuroactivos, composiciones, y usos de los mismos. - Google Patents
Esteroides neuroactivos, composiciones, y usos de los mismos.Info
- Publication number
- MX2023004352A MX2023004352A MX2023004352A MX2023004352A MX2023004352A MX 2023004352 A MX2023004352 A MX 2023004352A MX 2023004352 A MX2023004352 A MX 2023004352A MX 2023004352 A MX2023004352 A MX 2023004352A MX 2023004352 A MX2023004352 A MX 2023004352A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- disorders
- treatment
- compositions
- neuroactive steroids
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Se proporcionan en la presente compuestos de la Fórmula: (ver Fórmula) SA-6, y los usos del mismo en la manufactura de un medicamento para el tratamiento de un trastorno relacionado con el sistema nervioso central (CNS, por sus siglas en inglés) en un sujeto en necesidad del mismo. En una modalidad particular de la presente invención, en el trastorno relacionado con el CNS es un trastorno el sueño, un trastorno de humor, un trastorno del espectro de la esquizofrenia, un trastorno convulsivo, un trastorno de memoria y/o cognición, un trastorno de movimiento, un trastorno de personalidad, trastorno del espectro autista, dolor, lesión cerebral traumática, una enfermedad vascular, un trastorno por abuso de substancia o síndrome de abstinencia, y acúfenos. También se divulgan sales farmacéuticamente aceptables y composiciones farmacéuticas que comprenden dichos compuestos o sales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014078820 | 2014-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023004352A true MX2023004352A (es) | 2023-05-08 |
Family
ID=54698130
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016015532A MX2016015532A (es) | 2014-05-29 | 2015-05-29 | Esteroides neuroactivos, composiciones, y usos de los mismos. |
MX2021005099A MX2021005099A (es) | 2014-05-29 | 2016-11-25 | Esteroides neuroactivos, composiciones, y usos de los mismos. |
MX2023004352A MX2023004352A (es) | 2014-05-29 | 2016-11-25 | Esteroides neuroactivos, composiciones, y usos de los mismos. |
MX2021005106A MX2021005106A (es) | 2014-05-29 | 2016-11-25 | Esteroides neuroactivos, composiciones, y usos de los mismos. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016015532A MX2016015532A (es) | 2014-05-29 | 2015-05-29 | Esteroides neuroactivos, composiciones, y usos de los mismos. |
MX2021005099A MX2021005099A (es) | 2014-05-29 | 2016-11-25 | Esteroides neuroactivos, composiciones, y usos de los mismos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005106A MX2021005106A (es) | 2014-05-29 | 2016-11-25 | Esteroides neuroactivos, composiciones, y usos de los mismos. |
Country Status (26)
Country | Link |
---|---|
US (5) | US20180179247A1 (es) |
EP (3) | EP3705488B1 (es) |
JP (4) | JP6652934B2 (es) |
KR (2) | KR102494061B1 (es) |
CN (3) | CN106661078A (es) |
AR (2) | AR100691A1 (es) |
AU (4) | AU2015266447A1 (es) |
CA (1) | CA2949720A1 (es) |
CY (1) | CY1124109T1 (es) |
DK (2) | DK3705488T3 (es) |
ES (2) | ES2805598T3 (es) |
HR (2) | HRP20221294T1 (es) |
HU (2) | HUE059829T2 (es) |
IL (3) | IL292461B2 (es) |
JO (1) | JO3691B1 (es) |
LT (2) | LT3705488T (es) |
MX (4) | MX2016015532A (es) |
PH (1) | PH12016502342A1 (es) |
PL (2) | PL3705488T3 (es) |
PT (2) | PT3705488T (es) |
RS (2) | RS60529B1 (es) |
RU (2) | RU2699359C2 (es) |
SG (2) | SG11201609813XA (es) |
SI (2) | SI3705488T1 (es) |
TW (1) | TW201625661A (es) |
WO (1) | WO2015180679A1 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ568700A (en) | 2005-11-28 | 2012-03-30 | Marinus Pharmaceuticals | Solid stabilized particulate formulations comprising ganaxolone |
CN108976272B (zh) | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
KR20230172622A (ko) | 2013-04-17 | 2023-12-22 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
HUE051403T2 (hu) | 2013-04-17 | 2021-03-01 | Sage Therapeutics Inc | Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz |
PT3021852T (pt) | 2013-07-19 | 2021-04-21 | Sage Therapeutics Inc | Esteroides neuroativos, composições e utilizações das mesmas |
CA2921512A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
HRP20221294T1 (hr) * | 2014-05-29 | 2023-03-03 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, njihovi pripravci i uporabe |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
HUE051488T2 (hu) | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10780099B2 (en) | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
MA43815A (fr) * | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | Stéroïdes neuroactifs, compositions, et leurs utilisations |
AU2017296295B2 (en) * | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
RU2019103590A (ru) * | 2016-07-11 | 2021-02-11 | Сейдж Терапьютикс, Инк. | С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения |
KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
BR112020016269A2 (pt) | 2018-02-11 | 2020-12-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Reguladores derivados de esteroides, método para prepará- los e suas utilizações |
CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
KR20210116523A (ko) * | 2019-01-14 | 2021-09-27 | 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 | 테트라졸론 치환된 스테로이드 및 이의 용도 |
JP2022534424A (ja) | 2019-05-31 | 2022-07-29 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
JP2022543837A (ja) | 2019-08-05 | 2022-10-14 | マリナス ファーマシューティカルズ, インコーポレイテッド | てんかん重積状態の治療に使用するためのガナキソロン |
KR20220066262A (ko) | 2019-08-07 | 2022-05-24 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 스테로이드 유도체 조절제의 염 및 결정형 |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
JP2023503928A (ja) | 2019-12-06 | 2023-02-01 | マリナス ファーマシューティカルズ, インコーポレイテッド | 結節性硬化症の治療での使用のためのガナキソロン |
WO2022165017A1 (en) | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
KR20240037975A (ko) | 2021-07-28 | 2024-03-22 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드의 결정질 형태 |
WO2023164387A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
WO2024026337A1 (en) | 2022-07-27 | 2024-02-01 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3634717A1 (de) * | 1986-10-11 | 1988-04-14 | Dynamit Nobel Ag | Verfahren zur herstellung von 5-methyltetrazol |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
JP4066272B2 (ja) * | 1994-02-14 | 2008-03-26 | ユーロ‐セルティック エス. ア. | Gaba受容体のアロステリックな調節のためのアンドロスタン及びプレグナン類 |
AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
CA2372342A1 (en) * | 1999-04-29 | 2000-11-09 | Derk J. Hogenkamp | 3.alpha.-hydroxy-3.beta. methoxymethyl-21-heterocycle substituted steroids with anesthetic activity |
ATE537748T1 (de) * | 2002-10-15 | 2012-01-15 | Medtronic Inc | Medizinisches vorrichtungssystem zur bewertung von gemessenen neurologischen ereignissen |
US7729773B2 (en) * | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
CN108976272B (zh) * | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
HRP20221294T1 (hr) * | 2014-05-29 | 2023-03-03 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, njihovi pripravci i uporabe |
HUE051488T2 (hu) * | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
-
2015
- 2015-05-29 HR HRP20221294TT patent/HRP20221294T1/hr unknown
- 2015-05-29 IL IL292461A patent/IL292461B2/en unknown
- 2015-05-29 RU RU2016151727A patent/RU2699359C2/ru active
- 2015-05-29 SG SG11201609813XA patent/SG11201609813XA/en unknown
- 2015-05-29 TW TW104117532A patent/TW201625661A/zh unknown
- 2015-05-29 LT LTEP20171670.1T patent/LT3705488T/lt unknown
- 2015-05-29 JP JP2016569716A patent/JP6652934B2/ja active Active
- 2015-05-29 EP EP20171670.1A patent/EP3705488B1/en active Active
- 2015-05-29 AR ARP150101717A patent/AR100691A1/es active IP Right Grant
- 2015-05-29 RS RS20200799A patent/RS60529B1/sr unknown
- 2015-05-29 DK DK20171670.1T patent/DK3705488T3/da active
- 2015-05-29 EP EP15799762.8A patent/EP3149018B1/en active Active
- 2015-05-29 HU HUE20171670A patent/HUE059829T2/hu unknown
- 2015-05-29 SG SG10201803812TA patent/SG10201803812TA/en unknown
- 2015-05-29 KR KR1020167036320A patent/KR102494061B1/ko active IP Right Grant
- 2015-05-29 LT LTEP15799762.8T patent/LT3149018T/lt unknown
- 2015-05-29 CN CN201580039652.9A patent/CN106661078A/zh active Pending
- 2015-05-29 PL PL20171670.1T patent/PL3705488T3/pl unknown
- 2015-05-29 RS RS20220848A patent/RS63554B1/sr unknown
- 2015-05-29 HU HUE15799762A patent/HUE050028T2/hu unknown
- 2015-05-29 SI SI201531879T patent/SI3705488T1/sl unknown
- 2015-05-29 ES ES15799762T patent/ES2805598T3/es active Active
- 2015-05-29 WO PCT/CN2015/080216 patent/WO2015180679A1/en active Application Filing
- 2015-05-29 KR KR1020247014858A patent/KR20240066304A/ko active Application Filing
- 2015-05-29 AU AU2015266447A patent/AU2015266447A1/en not_active Abandoned
- 2015-05-29 PT PT201716701T patent/PT3705488T/pt unknown
- 2015-05-29 EP EP22187660.0A patent/EP4144746A1/en active Pending
- 2015-05-29 CN CN202111131937.9A patent/CN114133423A/zh active Pending
- 2015-05-29 PT PT157997628T patent/PT3149018T/pt unknown
- 2015-05-29 US US15/314,565 patent/US20180179247A1/en active Pending
- 2015-05-29 MX MX2016015532A patent/MX2016015532A/es unknown
- 2015-05-29 CN CN202110905603.6A patent/CN114369135A/zh active Pending
- 2015-05-29 CA CA2949720A patent/CA2949720A1/en active Pending
- 2015-05-29 ES ES20171670T patent/ES2927007T3/es active Active
- 2015-05-29 IL IL248948A patent/IL248948B/en unknown
- 2015-05-29 RU RU2019126637A patent/RU2019126637A/ru unknown
- 2015-05-29 IL IL304033A patent/IL304033A/en unknown
- 2015-05-29 DK DK15799762.8T patent/DK3149018T3/da active
- 2015-05-29 SI SI201531252T patent/SI3149018T1/sl unknown
- 2015-05-29 PL PL15799762T patent/PL3149018T3/pl unknown
- 2015-05-31 JO JOP/2015/0132A patent/JO3691B1/ar active
-
2016
- 2016-11-24 PH PH12016502342A patent/PH12016502342A1/en unknown
- 2016-11-25 MX MX2021005099A patent/MX2021005099A/es unknown
- 2016-11-25 MX MX2023004352A patent/MX2023004352A/es unknown
- 2016-11-25 MX MX2021005106A patent/MX2021005106A/es unknown
-
2019
- 2019-12-09 AU AU2019279910A patent/AU2019279910B2/en active Active
-
2020
- 2020-01-24 JP JP2020009771A patent/JP6892936B2/ja active Active
- 2020-01-31 US US16/778,975 patent/US20200165291A1/en not_active Abandoned
- 2020-07-17 HR HRP20201126TT patent/HRP20201126T1/hr unknown
- 2020-07-27 CY CY20201100683T patent/CY1124109T1/el unknown
- 2020-11-10 US US17/094,783 patent/US20210061849A1/en not_active Abandoned
- 2020-11-13 US US17/097,569 patent/US20210061850A1/en not_active Abandoned
-
2021
- 2021-03-25 AR ARP210100747A patent/AR121661A2/es unknown
- 2021-05-28 JP JP2021089953A patent/JP7386204B2/ja active Active
- 2021-06-28 AU AU2021204410A patent/AU2021204410B2/en active Active
-
2023
- 2023-07-10 JP JP2023113247A patent/JP2023123878A/ja active Pending
- 2023-10-06 US US18/482,079 patent/US20240076310A1/en active Pending
- 2023-12-19 AU AU2023285755A patent/AU2023285755A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023004352A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
MX2022007490A (es) | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. | |
CY1124175T1 (el) | Νευροδραστικα στεροειδη 19-nor για μεθοδους θεραπευτικης αντιμετωπισης | |
PH12016502581A1 (en) | TrK-INHIBITING COMPOUND | |
GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
PH12017502425A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
MX2023001876A (es) | Derivados de rapamicina. | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
SG10201909545XA (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
GEP20207172B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
MX2016015248A (es) | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. | |
MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
MY193740A (en) | "substituted 2,4 diamino-quinoline as new anticancer agents" | |
WO2011097946A8 (zh) | 含有并环稠合双环的噁唑烷酮化合物及其制备和应用 | |
PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
MX367647B (es) | Derivados de triazol fusionados como inhibidores de fosfodiesterasa 10a. | |
MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
MX2017009853A (es) | Prevencion o tratamiento de enfermedades urinarias o gotosas. | |
MD20160115A2 (ro) | Combinaţie nouă dintre 8-ciclopropil-3-[2-(3-fluorofenil)etil]-7,8-dihidro-3H-[1,3]oxazino[6,5-g][1,2,3]benzotriazin-4,9-dionă şi un inhibitor al acetilcolinesterazei şi compoziţii farmaceutice care o conţin |